FGFR2 and gastric cancer: Providing functional validation of these targets, combination treatment of an FGFR inhibitor and either an EGFR inhibitor (lapatinib) or an ILK inhibitor (Cpd22) synergistically inhibited the proliferation of FGFR2-altered GC cell lines [100]; however, whether these factors drive resistance in a clinical context remains to be demonstrated.